« Back
Home /
Torkinib (PP242)

Torkinib (PP242)

Item no.	M1981-25mg
Manufacturer	AbMole
CASRN	1092351-67-1
Amount	25mg
Category	Oncology Neuroscience Neural Signaling Inhibitors & Compound Libraries Small Molecules By Organ Heart & Blood Cancer Lymphatic System Cancer
Type	Inhibitors
Specific against	other
Purity	>99%
Citations	The PP242 mammalian target of rapamycin (mTOR) inhibitor activates extracellular signal-regulated kinase (ERK) in multiple myeloma cells via a target of rapamycin complex 1 (TORC1)/eukaryotic translation initiation factor 4E (eIF-4E)/RAF pathway and activation is a mechanism of resistance. Hoang B, et al . J Biol Chem. 2012 Jun 22,287(26):21796-805. PMID: 22556409 . Targeting TORC2 in multiple myeloma with a new mTOR kinase inhibitor. Hoang B, et al . Blood. 2010 Nov 25,116(22):4560-8. PMID: 20686120 . Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor. Janes MR, et al . Nat Med. 2010 Feb,16(2):205-13. PMID: 20072130 .
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	Torkinib
Similar products	PP242
Available
Molecular Weight	308, 34
Solubility	DMSO 50 mg/mL
Bioactivity information	Torkinib (PP242) is a selective, ATP-competitive mTORC1/mTORC2 inhibitor with IC50 of 8 nM.

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

M1981-25mg-safety-datasheet.pdf